Published in Blood Weekly, February 9th, 2006
Ev3's net sales in the fourth quarter of 2005 were $41 million, an increase of 60% versus net sales of $25.5 million in the fourth quarter of 2004.
This growth was broad-based and generated internally, reflecting strong sales growth from domestic and international markets as well as from both ev3's cardio peripheral and neurovascular business segments.
Cardio peripheral segment net sales in the fourth quarter were...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.